Orthofix Medical (OFIX) to Release Quarterly Earnings on Tuesday

Orthofix Medical (NASDAQ:OFIX) is scheduled to be posting its quarterly earnings results before the market opens on Tuesday, May 7th. Analysts expect Orthofix Medical to post earnings of ($0.32) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Orthofix Medical (NASDAQ:OFIX) last announced its quarterly earnings results on Tuesday, March 5th. The medical device company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.01. The firm had revenue of $200.42 million during the quarter. Orthofix Medical had a negative return on equity of 10.63% and a negative net margin of 20.28%. On average, analysts expect Orthofix Medical to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Orthofix Medical Stock Up 2.7 %

OFIX opened at $13.60 on Monday. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.20 and a current ratio of 2.54. The stock’s fifty day moving average is $13.62 and its two-hundred day moving average is $12.99. Orthofix Medical has a 52 week low of $9.57 and a 52 week high of $21.60.

Analysts Set New Price Targets

Several analysts recently weighed in on OFIX shares. StockNews.com downgraded Orthofix Medical from a “hold” rating to a “sell” rating in a report on Wednesday, March 6th. JMP Securities restated a “market perform” rating on shares of Orthofix Medical in a report on Monday, April 22nd. Finally, Roth Mkm increased their price objective on shares of Orthofix Medical from $12.00 to $15.00 and gave the company a “neutral” rating in a research note on Thursday, March 7th. One investment analyst has rated the stock with a sell rating and four have assigned a hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $15.50.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.